Home・Elenco Azioni・Celldex Therapeutics Inc

Celldex Therapeutics Inc

Aperta

SettoreSettore sanitario

39.07 4.27

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

37.29

Massimo

39.07

Metriche Chiave
By Trading Economics
Entrata	2.6M -79M
Vendite	-60K 15K
EPS	-1.18
Margine di Profitto	-524,566.667
Dipendenti	198
EBITDA	2.7M -78M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+51.02% upside

Dividendi
By Acuity
Utili prossimi	5 ago 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	226M 2.8B
Apertura precedente	34.8
Chiusura precedente	39.07

Notizie sul Sentiment di mercato

By Acuity

50%

151 / 340 Classifica in Healthcare

Celldex Therapeutics Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

3 ago 2026, 19:53 UTC

Celldex Therapeutics Inc. shares are lower as biotechnology stocks decline. The broader sector's weakness has influenced the stock's price action today.

31 lug 2026, 19:36 UTC

Celldex Therapeutics Inc. shares are lower today amid significant pressure on biotechnology stocks, with no specific company news identified to explain the decline.

30 lug 2026, 18:51 UTC

Celldex Therapeutics Inc is advancing during Thursday's session, moving higher alongside the broader market amid positive macroeconomic sentiment.

29 lug 2026, 20:03 UTC

Macro Event

News

Wells Fargo raised its price target on Celldex Therapeutics to $72, citing confidence in the company's growth prospects and promising pipeline. Shares are higher today.

28 lug 2026, 19:36 UTC

Shares of Celldex Therapeutics Inc. are lower today, continuing a decline since Monday's close, despite an earlier modest rebound from session lows.

27 lug 2026, 19:31 UTC

News

Celldex Therapeutics is higher today, bolstered by strong sentiment for its barzolvolimab program and successful Phase 3 enrollment for chronic spontaneous urticaria trials.

22 lug 2026, 20:01 UTC

Event

News

Social Media

Celldex Therapeutics is lower after discontinuing barzolvolimab development due to failed trial results. Wells Fargo lowered its price target to $48.

21 lug 2026, 23:01 UTC

Social Media

Event

News

Celldex Therapeutics shares fell in after-market hours following disappointing Phase 2 trial results for barzolvolimab, which failed to meet primary and secondary endpoints.

Confronto tra pari

Modifica del prezzo

Celldex Therapeutics Inc Previsione

Obiettivo di Prezzo

By TipRanks

51.02% in crescita

Previsioni per 12 mesi

Media 56.92 USD 51.02%

Alto 100 USD

Basso 34 USD

Basato su 14 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Celldex Therapeutics Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

14 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 14 che hanno fornito valutazioni azionarie a Celldex Therapeutics Inc - Dist negli ultimi 3 mesi.

Sentiment

By Acuity

151 / 340 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Celldex Therapeutics Inc

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.